Macromolecular Therapeutics Development

The Macromolecular Therapeutics Development Facility (MTDF) provides expertise for directed development and optimization of protein-based therapeutics and supports high-throughput automated development, analysis and production of protein reagents using a Bioemk Fx^P  liquid handling workstation for HTP molecular biology and expression testing, a Perkin-Elmer Cell::Explorer robot for very efficient HTP tissue culture based application and a custom microarray printer. This automation is designed to provide Einstein researchers with the added leverage of robotics equipment and trained personnel to accelerate and scale up their projects, thereby obviating the need for individual investigators to set up and staff their own facilities for protein production.

Monoclonal antibodies to tau proteins described by Dr. Peter Davies at Albert Einstein College of Medicine are available by contacting MTA@einsteinmed.edu. These antibodies, including MC-1, CP-13 and PHF-1, are proven tools in Alzheimer's research. Einstein is the only source for the antibodies purified from hybridoma culture. Previous work (described in US patent US9527909) showed that recombinant versions of MC-1 "displayed a myriad of issues including poor binding affinity, aggregation, HC dimerization, and chemical stability issues..." Versions of these antibodies purchased from sources other than Einstein may not have the functionality of the authentic antibodies described by the Davies group and subsequent researchers who have used the authentic antibodies.